Exchange Traded Concepts LLC Buys 3,103 Shares of Thermo Fisher Scientific Inc. $TMO

Exchange Traded Concepts LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 109.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,934 shares of the medical research company’s stock after purchasing an additional 3,103 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Thermo Fisher Scientific were worth $2,878,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Revolve Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. Lafayette Investments Inc. grew its position in shares of Thermo Fisher Scientific by 2.4% during the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after purchasing an additional 22 shares in the last quarter. Diversified Enterprises LLC increased its holdings in shares of Thermo Fisher Scientific by 1.6% in the third quarter. Diversified Enterprises LLC now owns 1,411 shares of the medical research company’s stock worth $684,000 after purchasing an additional 22 shares during the period. Challenger Wealth Management raised its position in shares of Thermo Fisher Scientific by 3.1% in the second quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock worth $298,000 after buying an additional 22 shares in the last quarter. Finally, Security National Bank of Sioux City Iowa IA grew its position in Thermo Fisher Scientific by 0.3% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 6,549 shares of the medical research company’s stock worth $2,655,000 after buying an additional 22 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $581.50 on Friday. The firm has a market cap of $218.48 billion, a PE ratio of 33.59, a price-to-earnings-growth ratio of 4.11 and a beta of 0.90. The company’s fifty day simple moving average is $573.11 and its two-hundred day simple moving average is $501.69. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its board has authorized a stock buyback plan on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Insider Buying and Selling

In other news, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the sale, the executive vice president owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. The trade was a 36.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 7,250 shares of the stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. The trade was a 5.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 149,271 shares of company stock valued at $86,507,282 over the last three months. Insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Barclays lifted their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Evercore ISI lifted their target price on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $616.60.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.